Pathological complete response in a POLE-mutated non-small cell lung cancer patient treated with perioperative chemoimmunotherapy: a case report and review of the literature.

doi:10.1007/s11684-026-1243-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pathological complete response in a POLE-mutated non-small cell lung cancer patient treated with perioperative chemoimmunotherapy: a case report and review of the literature.

MedScience - 1 Jun 2026

Liguori Luigi, De Feo Rosario, Santaniello Lucia, Miranda Brigida, Pagliara Valentina, Polcaro Giovanna, Caputo Alessandro, Cattaneo Giulia, Ventin Marco, Servetto Alberto, Ferrone Cristina R, Pepe Stefano, Sabbatino Francesco

Abstract excerpt

Immune checkpoint inhibitor (ICI)-based immunotherapy has emerged as an effective strategy for stage III non-small cell lung cancer (NSCLC). However, predictive biomarkers of response remain limited. DNA polymerase epsilon (POLE) mutations, although rare in NSCLC, are associated with an increased tumor mutational burden and enhanced neoantigen presentation, both of which may promote immune sensitivity. A...

Read the complete abstract on PubMed

Topics

Humans
Female
Middle Aged
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Pathologic Complete Response

Immunotherapy

DNA Polymerase II

Poly-ADP-Ribose Binding Proteins

Antibodies, Monoclonal, Humanized

Mutation

Carboplatin

Antineoplastic Combined Chemotherapy Protocols

Source

Open in PubMed

Identifiers

PMID: 42387111
DOI: 10.1007/s11684-026-1243-x

Genes

POLE

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathological complete response in a POLE-mutated non-small cell lung cancer patient treated with perioperative chemoimmunotherapy: a case report and review of the literature.PMID 42387111Read ↗

Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1Semantic proximity Read ↗

Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.Semantic proximity Read ↗

The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.Semantic proximity Read ↗

Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway.Semantic proximity Read ↗

Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies.Semantic proximity Read ↗

A randomized, open, multicenter Phase II study to explore the sequential use of chemotherapy and immunotherapy in postoperative adjuvant therapy for gastric or esophagogastric junction adenocarcinoma or colorectal adenocarcinoma with radical resection of POLE/POLD1 gene mutation or dMMR/MSI-HSemantic proximity Read ↗

Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer.Semantic proximity Read ↗

Rarity within rarity: complete response to chemoimmunotherapy in a patient with polymerase epsilon (POLE)-mutated locally advanced jejunal carcinoma.Semantic proximity Read ↗

Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation, EGFR mutation, and high microsatellite instability.Semantic proximity Read ↗

Impact of platinum-based chemotherapy on the tumor mutational burden and immune microenvironment in non-small cell lung cancer with postoperative recurrence.Semantic proximity Read ↗

Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.